完全经尿道切除术对肌层浸润性膀胱癌放射治疗后肿瘤学结果的影响。：放射治疗中的经尿道切除术。
Effect of complete transurethral resection on oncologic outcomes after radiation therapy for muscle-invasive bladder cancer.: Transurethral resection in radiation therapy.
发表日期：2024 Aug 24
作者：
Pier Paolo Avolio, Ronald Kool, Bobby Shayegan, Gautier Marcq, Peter C Black, Rodney H Breau, Michael Kim, Ionut Busca, Hamidreza Abdi, Mark Dawidek, Michael Uy, Gagan Fervaha, Fabio L Cury, Rafael Sanchez-Salas, Nimira Alimohamed, Jonathan Izawa, Claudio Jeldres, Ricardo Rendon, Robert Siemens, Girish S Kulkarni, Wassim Kassouf
来源：
Int J Radiat Oncol
摘要：
旨在比较放射治疗前接受完全性经尿道肿瘤切除术 (TURBT) 与不完全性经尿道肿瘤切除术 (TURBT) 的非转移性肌层浸润性膀胱癌 (MIBC) 患者的肿瘤学结果。 2002 年至2018年对十家加拿大机构进行了回顾性评估。使用基线特征进行治疗加权的逆概率。分析了完全和不完全 TURBT 的生存结果差异。在纳入的 757 名患者中，66% (498) 有完整 TURBT 记录，34% (259) 有不完整 TURBT 记录。调整前，分别有 121 名 (47%) 和 45 名 (9%) 接受不完全 TURBT 和完全 TURBT 的患者被诊断为 cT3-4 肿瘤 (p < 0.001)。体重调整后，所有基线队列特征均得到平衡（绝对标准化差异 < 0.1）。调整后的中位随访时间为 27 个月。调整后的生存分析显示，5 年总生存率（48% vs 52%，1.03 [0.82-1.29]；p=0.8）、癌症特异性生存率（64% vs 61%，0.93 [0.70-1.25]；p=0.8）没有显着差异。 p=0.7）、无转移生存率（43% vs 46%，0.97 [0.79-1.19]；p=0.8）和无病生存率（32% vs 35%，0.95 [0.79-1.15]；p=0.7 ）两组之间的差异。完全 TURBT 可能与临床器官局限性疾病相关。 TURBT 的程度与接受放射治疗的 MIBC 患者的肿瘤结局并不独立相关。版权所有 © 2024。由 Elsevier Inc. 出版。
To compare the oncologic outcomes of patients with non-metastatic muscle-invasive bladder cancer (MIBC) undergoing complete versus incomplete transurethral tumor resection (TURBT) prior to radiation therapy.Patients with non-metastatic MIBC who underwent curative-intent radiation therapy between 2002 and 2018 at ten Canadian institutions were retrospectively evaluated. Inverse probability of treatment weighting was performed using baseline characteristics. Differences in survival outcomes by complete and incomplete TURBT were analyzed.Of the 757 patients included, 66% (498) had documentation of a complete and 34% (259) an incomplete TURBT. Before adjustment, 121 (47%) and 45 (9%) patients who underwent incomplete and complete TURBT, respectively, were diagnosed with cT3-4 tumor (p < 0.001). After weight-adjustment, all baseline cohort characteristics were balanced (absolute standardized differences < 0.1). The adjusted median follow-up was 27 months. Adjusted survival analyses showed no significant difference in 5-year overall survival (48% vs 52%, 1.03 [0.82-1.29]; p = 0.8), cancer-specific survival (64% vs 61%, 0.93 [0.70-1.25]; p = 0.7), metastasis-free survival (43% vs 46%, 0.97 [0.79-1.19]; p = 0.8), and disease-free survival (32% vs 35%, 0.95 [0.79-1.15]; p = 0.7) between the two groups.Complete TURBT may be associated with clinical organ-confined disease. Extent of TURBT was not independently associated with oncologic outcomes in patients with MIBC treated with radiation therapy.Copyright © 2024. Published by Elsevier Inc.